Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 24

1.

The LIMD1 protein bridges an association between the prolyl hydroxylases and VHL to repress HIF-1 activity.

Foxler DE, Bridge KS, James V, Webb TM, Mee M, Wong SC, Feng Y, Constantin-Teodosiu D, Petursdottir TE, Bjornsson J, Ingvarsson S, Ratcliffe PJ, Longmore GD, Sharp TV.

Nat Cell Biol. 2012 Jan 29;14(2):201-8. doi: 10.1038/ncb2424.

PMID:
22286099
2.

Proline hydroxylation and gene expression.

Kaelin WG.

Annu Rev Biochem. 2005;74:115-28. Review.

PMID:
15952883
3.

Hypoxia-inducible factor as a therapeutic target for cardioprotection.

Ong SG, Hausenloy DJ.

Pharmacol Ther. 2012 Oct;136(1):69-81. doi: 10.1016/j.pharmthera.2012.07.005. Epub 2012 Jul 16. Review.

PMID:
22800800
4.

Involvement of oxygen-sensing pathways in physiologic and pathologic erythropoiesis.

Semenza GL.

Blood. 2009 Sep 3;114(10):2015-9. doi: 10.1182/blood-2009-05-189985. Epub 2009 Jun 3. Review.

5.

OS-9: another piece in the HIF complex story.

Flashman E, McDonough MA, Schofield CJ.

Mol Cell. 2005 Feb 18;17(4):472-3. Review.

6.

Regulation of HIF by the von Hippel-Lindau tumour suppressor: implications for cellular oxygen sensing.

Mole DR, Maxwell PH, Pugh CW, Ratcliffe PJ.

IUBMB Life. 2001 Jul;52(1-2):43-7. Review.

7.

Hypoxia-inducible factor 1 (HIF-1) pathway.

Semenza GL.

Sci STKE. 2007 Oct 9;2007(407):cm8. Review.

8.

Regulation of gene expression by the hypoxia-inducible factors.

Fedele AO, Whitelaw ML, Peet DJ.

Mol Interv. 2002 Jul;2(4):229-43. Review.

PMID:
14993394
9.

Von Hippel-Lindau tumor suppressor protein and hypoxia-inducible factor in kidney cancer.

Maynard MA, Ohh M.

Am J Nephrol. 2004 Jan-Feb;24(1):1-13. Epub 2003 Dec 3. Review.

10.

Nitric oxide and superoxide: interference with hypoxic signaling.

Brüne B, Zhou J.

Cardiovasc Res. 2007 Jul 15;75(2):275-82. Epub 2007 Mar 14. Review.

PMID:
17412315
11.

The role of HIF prolyl hydroxylases in tumour growth.

Jokilehto T, Jaakkola PM.

J Cell Mol Med. 2010 Apr;14(4):758-70. doi: 10.1111/j.1582-4934.2010.01030.x. Epub 2010 Feb 22. Review.

12.

HIF-1 mediates the Warburg effect in clear cell renal carcinoma.

Semenza GL.

J Bioenerg Biomembr. 2007 Jun;39(3):231-4. Review.

PMID:
17551816
13.

Nuclear-cytoplasmatic shuttling of proteins in control of cellular oxygen sensing.

Depping R, Jelkmann W, Kosyna FK.

J Mol Med (Berl). 2015 Jun;93(6):599-608. doi: 10.1007/s00109-015-1276-0. Epub 2015 Mar 27. Review.

PMID:
25809665
14.

Prolyl hydroxylase domain enzymes: important regulators of cancer metabolism.

Yang M, Su H, Soga T, Kranc KR, Pollard PJ.

Hypoxia (Auckl). 2014 Aug 30;2:127-142. eCollection 2014. Review.

15.

The human side of hypoxia-inducible factor.

Smith TG, Robbins PA, Ratcliffe PJ.

Br J Haematol. 2008 May;141(3):325-34. doi: 10.1111/j.1365-2141.2008.07029.x. Review.

16.

HIF hydroxylase pathways in cardiovascular physiology and medicine.

Bishop T, Ratcliffe PJ.

Circ Res. 2015 Jun 19;117(1):65-79. doi: 10.1161/CIRCRESAHA.117.305109. Review.

17.

Oxygen sensing in intestinal mucosal inflammation.

Flück K, Fandrey J.

Pflugers Arch. 2016 Jan;468(1):77-84. doi: 10.1007/s00424-015-1722-4. Epub 2015 Jul 25. Review.

PMID:
26206140
18.

[Advances of hypoxia and lung cancer].

Li X, You J, Zhou Q.

Zhongguo Fei Ai Za Zhi. 2013 Apr;16(4):216-20. doi: 10.3779/j.issn.1009-3419.2013.04.08. Review. Chinese.

19.

New Insights into Protein Hydroxylation and Its Important Role in Human Diseases.

Zurlo G, Guo J, Takada M, Wei W, Zhang Q.

Biochim Biophys Acta. 2016 Dec;1866(2):208-220. doi: 10.1016/j.bbcan.2016.09.004. Epub 2016 Sep 20. Review.

20.

Molecular mechanisms of action and therapeutic uses of pharmacological inhibitors of HIF-prolyl 4-hydroxylases for treatment of ischemic diseases.

Selvaraju V, Parinandi NL, Adluri RS, Goldman JW, Hussain N, Sanchez JA, Maulik N.

Antioxid Redox Signal. 2014 Jun 1;20(16):2631-65. doi: 10.1089/ars.2013.5186. Epub 2013 Oct 31. Review.

Supplemental Content

Support Center